跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
簡 麗年
教授
衛生福利研究所
https://orcid.org/0000-0001-9441-552X
電話
02-2826-7000#67066
電子郵件
linien.chien
nycu.edu
tw
h-index
h10-index
h5-index
1432
引文
21
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1087
引文
19
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
392
引文
11
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2003
2025
每年研究成果
概覽
指紋
網路
研究成果
(104)
類似的個人檔案
(6)
指紋
查看啟用 Li-Nien Chien 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Acute Myocardial Infarction
24%
Adjusted Hazard Ratio
28%
Adjusted Odds Ratio
7%
All-cause Mortality
9%
Anemia
9%
Aspirin
8%
Breast Cancer Prevention
15%
Cervical Cancer
7%
Cervical Cancer Prevention
16%
Clinical Outcomes
8%
Comorbidity
9%
Confidence Interval
58%
Dementia Risk
8%
Drug-eluting Stent
14%
Drug-eluting Stent Implantation
11%
Dry Eye
9%
End-stage Renal Disease
13%
Epidemiology
9%
Epilepsy
12%
Georgia
14%
High Risk
13%
Hospitalization
12%
Incidence Rate
9%
Ischemic Stroke
11%
Kidney Disease Progression
8%
Low Risk
13%
Medicaid
12%
Metformin
9%
Myocardial Infarction
8%
National Cohort Study
45%
National Health Insurance Research Database (NHIRD)
13%
Nested Case-control Study
18%
Newly Diagnosed
10%
Parkinson's Disease
13%
Patients with Diabetes
11%
Percutaneous Coronary Intervention
13%
Population-based
7%
Population-based Cohort Study
33%
Population-based Study
16%
Post-stroke Epilepsy
9%
Risk Factors
12%
ST-elevation Myocardial Infarction (STEMI)
14%
Subdistribution Hazard Ratio
7%
Taiwan
100%
Taiwan National Health Insurance Research Database
9%
Taiwanese
7%
Total Hip Replacement
9%
Treatment Patterns
10%
Type 1 Diabetes Mellitus (T1DM)
7%
Type 2 Diabetes Mellitus (T2DM)
7%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylsalicylic Acid
9%
Acute Heart Infarction
24%
Acute Myeloid Leukemia
6%
All Cause Mortality
5%
Alzheimer's Disease
6%
Anticonvulsive Agent
6%
Antiplatelet
10%
Atrial Fibrillation
9%
Bleeding
8%
Brain Ischemia
11%
Breast Cancer
12%
Cardiogenic Shock
6%
Cardiovascular Disease
5%
Case-Control Study
15%
Cerebrovascular Accident
21%
Chemotherapy
5%
Chronic Obstructive Lung Disease
9%
Clopidogrel
6%
Cohort Study
60%
Comorbidity
12%
Congestive Heart Failure
10%
Diabetes Mellitus
8%
Diseases
12%
Dry Eye
9%
End Stage Renal Disease
12%
Eye Disease
9%
Gastroesophageal Reflux
6%
Glaucoma
6%
Heart Infarction
10%
Hemodialysis
9%
Hepatitis B
6%
Hepatitis B Virus
6%
Kidney Disease
7%
Lung Cancer
9%
Metformin
10%
New-Onset Atrial Fibrillation
6%
Non Insulin Dependent Diabetes Mellitus
14%
Non ST Segment Elevation Myocardial Infarction
8%
Parkinson's Disease
9%
Phenytoin
6%
Respiratory Failure
5%
Rivaroxaban
6%
Seroprevalence
6%
Sodium Valproate
6%
ST Segment Elevation Myocardial Infarction
7%
Statin (Protein)
6%
Survival Rate
5%
Uterine Cervix Cancer
12%
Warfarin
6%
Medicine and Dentistry
Acute Heart Infarction
11%
Acute Myeloid Leukemia
6%
Alzheimer's Disease
6%
Anemia
9%
Apoplexy
15%
Autism
6%
Brain Ischemia
10%
Breast Cancer
10%
Breast Cancer Prevention
15%
Cancer Registry
6%
Cancer Therapy
18%
Cardiogenic Shock
6%
Case-Control Study
9%
Cervical Cancer
9%
Cervical Cancer Prevention
15%
Charlson Comorbidity Index
5%
Chronic Obstructive Pulmonary Disease
6%
Cohort Analysis
35%
Cohort Effect
9%
Comorbidity
14%
Compression Fracture
6%
Congestive Heart Failure
9%
Diabetes Mellitus
5%
Diseases
9%
Drug-Eluting Stent
15%
Dry Eye
6%
End Stage Renal Disease
8%
Eye Disease
6%
Fatality
6%
Hazard Ratio
30%
Hemodialysis
6%
Hip Replacement
6%
Logistic Regression Analysis
5%
Lung Cancer
9%
Medicaid
7%
Nephropathy
6%
New-Onset Atrial Fibrillation
6%
Overall Survival
5%
Parkinson's Disease
9%
Percutaneous Coronary Intervention
6%
Percutaneous Vertebroplasty
6%
Proportional Hazards Model
8%
Proton-Pump Inhibitor
6%
Reoperation
6%
Respiratory Failure
5%
Retrospective Cohort Study
5%
ST Segment Elevation Myocardial Infarction
5%
Surgeon
6%
Survival Rate
6%
Womens Health
6%
